tetano
Editor, Senior Moderator
Sci Rep
. 2022 Nov 30;12(1):20628.
doi: 10.1038/s41598-022-24464-3.
Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing
Hideharu Hagiya[SUP] 1 [/SUP], Yasuhiro Nakano[SUP] 2 [/SUP], Masanori Furukawa[SUP] 3 [/SUP], Naruhiko Sunada[SUP] 2 [/SUP], Toru Hasegawa[SUP] 2 [/SUP], Yasue Sakurada[SUP] 2 [/SUP], Kou Hasegawa[SUP] 2 [/SUP], Koichiro Yamamoto[SUP] 2 [/SUP], Hiroko Ogawa[SUP] 2 [/SUP], Takafumi Obara[SUP] 4 [/SUP], Kouhei Ageta[SUP] 4 [/SUP], Naomi Matsumoto[SUP] 5 [/SUP], Rumi Matsuo[SUP] 5 [/SUP], Tomoka Kadowaki[SUP] 5 [/SUP], Akihito Higashikage[SUP] 3 [/SUP], Takao Hikita[SUP] 6 7 [/SUP], Takashi Yorifuji[SUP] 5 [/SUP], Shinichi Toyooka[SUP] 8 [/SUP], Yoshinobu Maeda[SUP] 9 [/SUP], Yoshinori Yokokura[SUP] 10 [/SUP], Fumio Otsuka[SUP] 2 3 [/SUP], Masanori Nakayama[SUP] 11 12 [/SUP]
Affiliations
Abstract
Amid the Coronavirus Disease 2019 pandemic, we aimed to demonstrate the accuracy of the fingertip whole blood sampling test (FWT) in measuring the antibody titer and uncovering its dynamics shortly after booster vaccination. Mokobio SARS-CoV-2 IgM & IgG Quantum Dot immunoassay (Mokobio Biotechnology R&D Center Inc., MD, USA) was used as a point-of-care FWT in 226 health care workers (HCWs) who had received two doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) at least 8 months prior. Each participant tested their antibody titers before and after the third-dose booster up to 14-days. The effect of the booster was observed as early as the fourth day after vaccination, which exceeded the detection limit (> 30,000 U/mL) by 2.3% on the fifth day, 12.2% on the sixth day, and 22.5% after the seventh day. Significant positive correlations were observed between the pre- and post-vaccination (the seventh and eighth days) antibody titers (correlation coefficient, 0.405; p < 0.001). FWT is useful for examining antibody titers as a point-of-care test. Rapid response of antibody titer started as early as the fourth day post-vaccination, while the presence of weak responders to BNT162b2 vaccine was indicated.
. 2022 Nov 30;12(1):20628.
doi: 10.1038/s41598-022-24464-3.
Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing
Hideharu Hagiya[SUP] 1 [/SUP], Yasuhiro Nakano[SUP] 2 [/SUP], Masanori Furukawa[SUP] 3 [/SUP], Naruhiko Sunada[SUP] 2 [/SUP], Toru Hasegawa[SUP] 2 [/SUP], Yasue Sakurada[SUP] 2 [/SUP], Kou Hasegawa[SUP] 2 [/SUP], Koichiro Yamamoto[SUP] 2 [/SUP], Hiroko Ogawa[SUP] 2 [/SUP], Takafumi Obara[SUP] 4 [/SUP], Kouhei Ageta[SUP] 4 [/SUP], Naomi Matsumoto[SUP] 5 [/SUP], Rumi Matsuo[SUP] 5 [/SUP], Tomoka Kadowaki[SUP] 5 [/SUP], Akihito Higashikage[SUP] 3 [/SUP], Takao Hikita[SUP] 6 7 [/SUP], Takashi Yorifuji[SUP] 5 [/SUP], Shinichi Toyooka[SUP] 8 [/SUP], Yoshinobu Maeda[SUP] 9 [/SUP], Yoshinori Yokokura[SUP] 10 [/SUP], Fumio Otsuka[SUP] 2 3 [/SUP], Masanori Nakayama[SUP] 11 12 [/SUP]
Affiliations
- PMID: 36450786
- DOI: 10.1038/s41598-022-24464-3
Abstract
Amid the Coronavirus Disease 2019 pandemic, we aimed to demonstrate the accuracy of the fingertip whole blood sampling test (FWT) in measuring the antibody titer and uncovering its dynamics shortly after booster vaccination. Mokobio SARS-CoV-2 IgM & IgG Quantum Dot immunoassay (Mokobio Biotechnology R&D Center Inc., MD, USA) was used as a point-of-care FWT in 226 health care workers (HCWs) who had received two doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) at least 8 months prior. Each participant tested their antibody titers before and after the third-dose booster up to 14-days. The effect of the booster was observed as early as the fourth day after vaccination, which exceeded the detection limit (> 30,000 U/mL) by 2.3% on the fifth day, 12.2% on the sixth day, and 22.5% after the seventh day. Significant positive correlations were observed between the pre- and post-vaccination (the seventh and eighth days) antibody titers (correlation coefficient, 0.405; p < 0.001). FWT is useful for examining antibody titers as a point-of-care test. Rapid response of antibody titer started as early as the fourth day post-vaccination, while the presence of weak responders to BNT162b2 vaccine was indicated.